cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: a markov model based on data a balkan country in socioeconomic transition
Clicks: 218
ID: 250622
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
218 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #119 of 134 articles by views in applied nursing research : anr
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 134 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background/Aim. A cost-effectiveness analyses of immunomodulatory treatments for relapsing-remitting multiple sclerosis (RRMS) in developed countries have shown that any benefit from these drugs is achieved at very high cost. The aim of our study was to compare the cost-effectiveness of five treatment strategies in patients diagnosed with RRMS (symptom management alone and in combination with subcutaneous glatiramer acetate, intramuscular interferon β-1a, subcutaneous interferon β-1a, or intramuscular interferon β- 1b) in a Balkan country in socio-economic transition. Methods. The Markov model was developed based on the literature about effectiveness and on local Serbian cost calculations. The duration of a cycle in the model was set to a month. The baseline time horizon was 480 months (40 years). The societal perspective was used for costs and outcomes, and they were discounted for 3% annually. Monte Carlo micro simulation with 1000 virtual patients was done. Results. Significant gain with immunomodulatory therapy was achieved only in relapse-free years, while the time spent in health states EDSS 0.0-5.5 was longer with symptomatic therapy only, and gains in life years and QALYs were only marginal. One QALY gained costs more than a billion of Serbian dinars (more than 20 million US dollars), making each of the four immunomodulatory therapies costineffective. Conclusion. Our study suggests that immunomodulatory therapy of RRMS in a Balkan country in socioeconomic transition is not cost-effective, regardless of the type of the therapy. Moderate gain in relapse-free years does not translate to gain in QALYs, probably due to adverse effects of immunomodulatory therapy.
| Reference Key |
m.2009vojnosanitetskicost-effectiveness
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Janković Slobodan M.;Kostić Marina;Radosavljević Marija;Tešić Danka;Stefanović-Stoimenov Nataša;Stevanović Ivan;Raković Slađana;Aleksić Jelena;Folić Marko;Aleksić Aleksandra;Mihajlović Ivana;Biorac Nenad;Borlja Jelena;Vučković Radosava |
| Journal | applied nursing research : anr |
| Year | 2009 |
| DOI |
10.2298/VSP0907556J
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.